Should I buy or sell Revelation Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revelation Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" REVB shares. View REVB analyst ratings or view top-rated stocks .

What is Revelation Biosciences' stock price target for 2024?

1 Wall Street analysts have issued 12 month price objectives for Revelation Biosciences' shares. Their REVB share price targets range from $450.00 to $450.00. On average, they predict the company's stock price to reach $450.00 in the next year. This suggests a possible upside of 16,087.1% from the stock's current price. View analysts price targets for REVB or view top-rated stocks among Wall Street analysts .

How have REVB shares performed in 2024?

Revelation Biosciences' stock was trading at $15.0210 at the beginning of 2024. Since then, REVB stock has decreased by 81.5% and is now trading at $2.78. View the best growth stocks for 2024 here .

When is Revelation Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our REVB earnings forecast .

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (NASDAQ:REVB) posted its earnings results on Tuesday, January, 29th. The company reported $619.50 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $640.50 by $21.00. The company earned $22.79 million during the quarter, compared to the consensus estimate of $22.20 million.

When did Revelation Biosciences' stock split?

Revelation Biosciences's stock reverse split before market open on Thursday, January 25th 2024. The 1-30 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Revelation Biosciences?

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:REVB

Revelation Biosciences (REVB) Stock Price, News & Analysis

$2.78

0.00 (0.00%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $2.62
▼
$3.05
50-Day Range: $2.58
▼
$22.94
52-Week Range: $2.40
▼
$91.20

Volume: 901,700 shs
Average Volume: 526,527 shs
Market Capitalization: $583,800.00

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $450.00

Get Revelation Biosciences alerts:

Revelation Biosciences MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 16,087.1% Upside
$450.00 Price Target
Short Interest: Bearish
9.31% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.03
Based on 4 Articles This Week
Insider Trading: Selling Shares
$14,430 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($38.74) to ($46.25) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.86 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Revelation Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $450.00, Revelation Biosciences has a forecasted upside of 16,087.1% from its current price of $2.78.
Amount of Analyst Coverage
Revelation Biosciences has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.31% of the float of Revelation Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Revelation Biosciences has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Revelation Biosciences has recently increased by 27.74%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Revelation Biosciences does not currently pay a dividend.
Dividend Growth
Revelation Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for REVB.

3.9

News and Social Media Coverage

News Sentiment
Revelation Biosciences has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Revelation Biosciences this week, compared to 0 articles on an average week.
Search Interest
6 people have searched for REVB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
MarketBeat Follows
5 people have added Revelation Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revelation Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $14,430.00 in company stock.
Percentage Held by Insiders
Only 1.40% of the stock of Revelation Biosciences is held by insiders.
Percentage Held by Institutions
Only 12.80% of the stock of Revelation Biosciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Revelation Biosciences are expected to decrease in the coming year, from ($38.74) to ($46.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revelation Biosciences is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revelation Biosciences is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Revelation Biosciences has a P/B Ratio of 0.06. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Revelation Biosciences Stock (NASDAQ:REVB)

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, urinary tract infection, sepsis, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

REVB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

REVB Stock News Headlines

February 9, 2024 | msn.com

Revelation Biosciences Secures $6.2M in Public Offering

February 5, 2024 | finance.yahoo.com

Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering

February 12, 2024 | The Freeport Society (Ad)

Obama’s 2024 Confession

Barack Obama’s confession about the 2024 election just leaked online… In short, he’s worried Biden “could very well lose.” But before you think that means Trump will win… You should see the evidence I’ve found about an election shock that could come as soon as August 19th.

February 2, 2024 | marketwatch.com

Revelation Biosciences Shares Slide Premarket on Public Offering

February 1, 2024 | msn.com

Revelation Biosciences to raise ~$6.2M through public offering of shares

February 1, 2024 | investorplace.com

Why Is Revelation Biosciences (REVB) Stock Down 62% Today?

January 30, 2024 | finance.yahoo.com

Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024)

January 29, 2024 | seekingalpha.com

FATE, NEXI and INBS among mid-day movers

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

January 26, 2024 | finance.yahoo.com

REVB Continues March to Trials

January 23, 2024 | finance.yahoo.com

Revelation Biosciences Inc. Announces 1-for-30 Reverse Stock Split Effective January 25, 2024

November 22, 2023 | morningstar.com

Revelation Biosciences Inc Ordinary Shares REVB

November 14, 2023 | finance.yahoo.com

REVB Releases Earnings and Prepares for Trials

November 14, 2023 | msn.com

Revelation Biosciences GAAP EPS of -$0.42

November 13, 2023 | finance.yahoo.com

Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2023

October 12, 2023 | finance.yahoo.com

Gemini Induces Pharmacologic Activity and Related Physiologic Changes in Multiple Preclinical Studies

October 4, 2023 | finance.yahoo.com

Revelation Biosciences, Inc. to Present at the 2023 ROTH Healthcare Opportunities Conference

October 2, 2023 | finance.yahoo.com

Revelation Biosciences Inc. Announces Appointment of Lakhmir Chawla, M.D. to Board of Directors

August 14, 2023 | finance.yahoo.com

REVB Reports Solid Balance Sheet and Remains on Track

August 11, 2023 | finance.yahoo.com

Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2023

June 29, 2023 | finance.yahoo.com

REMINDER: Revelation Biosciences, Inc. Urges All Stockholders to Vote at the 2023 Annual Meeting of Stockholders

June 22, 2023 | finance.yahoo.com

REVB: REVB Looks Attractive Ahead of Trials

June 12, 2023 | finance.yahoo.com

Revelation Biosciences Inc. Announces Adjournment of 2023 Annual Meeting of Stockholders to July 7, 2023 and Additional Proposal

June 6, 2023 | finance.yahoo.com

REVB - Revelation Biosciences, Inc.

May 22, 2023 | seekingalpha.com

Revelation Biosciences GAAP EPS of $1.96

May 22, 2023 | finance.yahoo.com

Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress

March 30, 2023 | finance.yahoo.com

Revelation Biosciences Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2022 and Recent Corporate Progress

See More Headlines

Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 1/29/2019
Today: 2/12/2024
Next Earnings (Estimated): 4/04/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:REVB
CUSIP: N/A
CIK: 1810560
Web: www.revbiosciences.com
Phone: 650-800-3717
Fax: N/A
Employees: 6
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $450.00
High Stock Price Target: $450.00
Low Stock Price Target: $450.00
Potential Upside/Downside: +16,087.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($14.4144)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,830,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -86.60%
Return on Assets: -50.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.62
Quick Ratio: 2.62

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $46.26 per share
Price / Book: 0.06

Miscellaneous

Outstanding Shares: 210,000
Free Float: 207,000
Market Cap: $583,800.00
Optionable: Not Optionable
Beta: 0.37

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. James M. Rolke (Age 55)
CEO & Director
Comp: $400k
Mr. Chester Stanley Zygmont III (Age 44)
CFO & Corporate Secretary
Comp: $320k
Ms. Sandra Vedrick
Vice President of Human Resources & Investor Relations
Ms. Carol Odle
Senior Director of Clinical Projects

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REVB Stock Analysis - Frequently Asked Questions

Should I buy or sell Revelation Biosciences stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revelation Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" REVB shares.
View REVB analyst ratings or view top-rated stocks.
What is Revelation Biosciences' stock price target for 2024?: 1 Wall Street analysts have issued 12 month price objectives for Revelation Biosciences' shares. Their REVB share price targets range from $450.00 to $450.00. On average, they predict the company's stock price to reach $450.00 in the next year. This suggests a possible upside of 16,087.1% from the stock's current price.
View analysts price targets for REVB or view top-rated stocks among Wall Street analysts.
How have REVB shares performed in 2024?: Revelation Biosciences' stock was trading at $15.0210 at the beginning of 2024. Since then, REVB stock has decreased by 81.5% and is now trading at $2.78.
View the best growth stocks for 2024 here.
When is Revelation Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our REVB earnings forecast.

How were Revelation Biosciences' earnings last quarter?: Revelation Biosciences, Inc. (NASDAQ:REVB) posted its earnings results on Tuesday, January, 29th. The company reported $619.50 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $640.50 by $21.00. The company earned $22.79 million during the quarter, compared to the consensus estimate of $22.20 million.
When did Revelation Biosciences' stock split?: Revelation Biosciences's stock reverse split before market open on Thursday, January 25th 2024. The 1-30 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
How do I buy shares of Revelation Biosciences?: Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:REVB) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial